North America Adalimumab Market to 2032
Overview
The North America Adalimumab Market is expected to reach a 27,866.39 USD Billion by 2032 and is projected to grow at a CAGR of 7.97% from 2025 to 2032.
Revenue, 2024 (USD Billion)
18,593.52
Forecast, 2032 (USD Billion)
27,866.39
CAGR, 2024 - 2032
7.97%
Report Coverage
North America
North America Adalimumab Market 2018-2032 USD Billion
North America Adalimumab Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 18,593.52 USD Billion
- Projected Market Size (2032): 27,866.39 USD Billion
- CAGR (2025-2032): 7.97%
Key Findings of North America Adalimumab Market
- The North America Adalimumab Market was valued at 18,593.52 USD Billion in 2024.
- The North America Adalimumab Market is likely to grow at a CAGR of 7.97% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Parenteral (SC) in Route of Administration Segment accounted for the largest share of the market with a revenue of 18,593.52 USD Billion
- The fastest growing segment Ankylosing Spondylitis in Indication Segment grew Fastest with a CAGR of 9.34% during the forecast period from 2024 to 2032.
North America Adalimumab Market Scope
North America Adalimumab Market Segmentation & Scope
Distribution Channel
- Others
- Direct Tenders
- Online Pharmacies
- Retail Pharmacies
- Hospital Pharmacies
End User
- Others
- Home Healthcare
- Specialty Clinics
- Hospitals
Drug Type
- Generics
- Branded
Route of Administration
- Oral
- Parenteral (SC)
Population Type
- Children
- Adults
Dosage Strength
- Others
- 10mg/0.1ml
- 20mg/0.4ml
- 80mg/0.8ml
- 40mg/0.4ml
Indication
- Others
- Non-Infectious Intermediate
- Hidradenitis Suppurativa
- Juvenile Idiopathic Arthritis
- Psoriatic Arthritis
- Ulcerative Colitis
- Crohn's Disease
- Chronic Plaque Psoriasis
- Ankylosing Spondylitis
- Rheumatoid Arthritis
Type
- Biosimilars
- Biologics
North America Adalimumab Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2020 |
| Unit | Revenue in USD Billion |
| Market Value in 2024 | 18,593.52 USD Billion |
| Market Value in 2032 | 27,866.39 USD Billion |
| CAGR (2025-2032) | 7.97% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Distribution Channel,End User,Drug Type,Route of Administration,Population Type,Dosage Strength,Indication,Type |
Regional Insights:
-
Leading Market (2024-2032): North America, leading in terms of revenue 18,593.52 USD Billion in 2024
- Key Country: U.S., leading in terms of revenue with value of 18,128.92 USD Billion in 2024.
Segments and Scope
-
North America Adalimumab Market to 2032, By Distribution Channel
- Hospital Pharmacies is the largest segment in North America Adalimumab Market to 2032 with a revenue of 9,509.08 USD Billion in the year 2024.
- Retail Pharmacies is the Fastest growing segment in North America Adalimumab Market to 2032 with a Growth rate of 8.15 % in forecast period 2025-2032.
-
North America Adalimumab Market to 2032, By End User
- Hospitals is the largest segment in North America Adalimumab Market to 2032 with a revenue of 8,180.39 USD Billion in the year 2024.
- Specialty Clinics is the Fastest growing segment in North America Adalimumab Market to 2032 with a Growth rate of 7.28 % in forecast period 2025-2032.
-
North America Adalimumab Market to 2032, By Drug Type
- Branded is the largest segment in North America Adalimumab Market to 2032 with a revenue of 10,411.03 USD Billion in the year 2024.
- Generics is the Fastest growing segment in North America Adalimumab Market to 2032 with a Growth rate of -13.00 % in forecast period 2025-2032.
-
North America Adalimumab Market to 2032, By Route of Administration
- Parenteral (SC) is the largest segment in North America Adalimumab Market to 2032 with a revenue of 18,593.52 USD Billion in the year 2024.
- Parenteral (SC) is the Fastest growing segment in North America Adalimumab Market to 2032 with a Growth rate of 7.97 % in forecast period 2025-2032.
-
North America Adalimumab Market to 2032, By Population Type
- Adults is the largest segment in North America Adalimumab Market to 2032 with a revenue of 12,489.10 USD Billion in the year 2024.
- Children is the Fastest growing segment in North America Adalimumab Market to 2032 with a Growth rate of 7.67 % in forecast period 2025-2032.
-
North America Adalimumab Market to 2032, By Dosage Strength
- 40mg/0.4ml is the largest segment in North America Adalimumab Market to 2032 with a revenue of 6,568.62 USD Billion in the year 2024.
- 40mg/0.4ml is the Fastest growing segment in North America Adalimumab Market to 2032 with a Growth rate of 9.30 % in forecast period 2025-2032.
-
North America Adalimumab Market to 2032, By Indication
- Rheumatoid Arthritis is the largest segment in North America Adalimumab Market to 2032 with a revenue of 4,722.89 USD Billion in the year 2024.
- Ankylosing Spondylitis is the Fastest growing segment in North America Adalimumab Market to 2032 with a Growth rate of 8.10 % in forecast period 2025-2032.
-
North America Adalimumab Market to 2032, By Type
- Biologics is the largest segment in North America Adalimumab Market to 2032 with a revenue of 10,411.03 USD Billion in the year 2024.
- Biosimilars is the Fastest growing segment in North America Adalimumab Market to 2032 with a Growth rate of -13.00 % in forecast period 2025-2032.
North America Adalimumab Market Company Share Analysis
North America Adalimumab Market Geographical Sales Distribution, 2018-2032 USD Billion
North America Adalimumab Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The North America Adalimumab Market is segmented based on Segmentation Distribution Channel,End User,Drug Type,Route of Administration,Population Type,Dosage Strength,Indication,Type.
North America Adalimumab Market was valued at USD 18,593.52(Revenue in USD Billion) in 2020.
North America Adalimumab Market is projected to grow at a CAGR of 7.97% during the forecast period of 2024 to 2032.
The Parenteral (SC) segment is expected to dominate the North America Adalimumab Market, holding a largest market share of 18,593.52 USD Billion in 2024
North America Adalimumab Market Scope
North America Adalimumab Market Segmentation & Scope
Distribution Channel
- Others
- Direct Tenders
- Online Pharmacies
- Retail Pharmacies
- Hospital Pharmacies
End User
- Others
- Home Healthcare
- Specialty Clinics
- Hospitals
Drug Type
- Generics
- Branded
Route of Administration
- Oral
- Parenteral (SC)
Population Type
- Children
- Adults
Dosage Strength
- Others
- 10mg/0.1ml
- 20mg/0.4ml
- 80mg/0.8ml
- 40mg/0.4ml
Indication
- Others
- Non-Infectious Intermediate
- Hidradenitis Suppurativa
- Juvenile Idiopathic Arthritis
- Psoriatic Arthritis
- Ulcerative Colitis
- Crohn's Disease
- Chronic Plaque Psoriasis
- Ankylosing Spondylitis
- Rheumatoid Arthritis
Type
- Biosimilars
- Biologics
Frequently Asked Questions
The North America Adalimumab Market is segmented based on Segmentation Distribution Channel,End User,Drug Type,Route of Administration,Population Type,Dosage Strength,Indication,Type.
North America Adalimumab Market was valued at USD 18,593.52(Revenue in USD Billion) in 2020.
North America Adalimumab Market is projected to grow at a CAGR of 7.97% during the forecast period of 2024 to 2032.
The estimated market value of the North America Adalimumab Market for final year is USD 27,866.39 (USD Billion).
North America Adalimumab Market Company Profiling
Frequently Asked Questions
The North America Adalimumab Market is segmented based on Segmentation Distribution Channel,End User,Drug Type,Route of Administration,Population Type,Dosage Strength,Indication,Type.
North America Adalimumab Market was valued at USD 18,593.52(Revenue in USD Billion) in 2020.
North America Adalimumab Market is projected to grow at a CAGR of 7.97% during the forecast period of 2024 to 2032.
The estimated market value of the North America Adalimumab Market for final year is USD 27,866.39 (USD Billion).
CHOOSE LICENCE TYPE
- 4200.00
- 3500.00
- 2000.00
- 5500.00
- 8500.00
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.